Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study.

Russell M, Silverman A, Fleg JL, Lee ET, Mete M, Weir M, Wilson C, Yeh F, Howard BV, Howard WM.

J Clin Lipidol. 2010 Sep-Oct;4(5):435-43. doi: 10.1016/j.jacl.2010.07.007.

2.

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, Wilson C, Stylianou M, Howard WJ.

J Am Coll Cardiol. 2008 Dec 16;52(25):2198-205. doi: 10.1016/j.jacc.2008.10.031.

3.

2017 Taiwan lipid guidelines for high risk patients.

Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI; Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients.

J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. Review.

4.

Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience.

Mete M, Wilson C, Lee ET, Silverman A, Russell M, Stylianou M, Umans JG, Wang W, Howard WJ, Ratner RE, Howard BV, Fleg JL.

J Diabetes Complications. 2011 Nov-Dec;25(6):362-7. doi: 10.1016/j.jdiacomp.2011.04.001. Epub 2011 Jul 19.

5.

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.

Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM.

Atherosclerosis. 2012 Aug;223(2):251-61. doi: 10.1016/j.atherosclerosis.2012.02.016. Epub 2012 Feb 16. Review.

PMID:
22410123
6.

Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.

Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D.

Int Angiol. 2010 Dec;29(6):514-24.

PMID:
21173733
7.

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.

Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B.

Curr Med Res Opin. 2004 Sep;20(9):1437-45.

PMID:
15383192
8.

Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.

Rotella CM, Zaninelli A, Le Grazie C, Hanson ME, Gensini GF.

Lipids Health Dis. 2010 Jul 27;9:80. doi: 10.1186/1476-511X-9-80.

9.

[Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].

Brath H, Wascher TC, Kästenbauer T, Toplak H.

MMW Fortschr Med. 2012 Jun 28;154 Suppl 2:41-7. German.

PMID:
23424754
10.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
11.
12.
13.

Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS) .

Wilson C, Huang CC, Shara N, Howard BV, Fleg JL, Henderson JA, Howard WJ, Huentelman H, Lee ET, Mete M, Russell M, Galloway JM, Silverman A, Stylianou M, Umans J, Weir MR, Yeh F, Ratner RE.

J Clin Lipidol. 2010 May-Jun;4(3):165-72. doi: 10.1016/j.jacl.2010.01.008.

14.

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial.

Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russell M, Silverman A, Stylianou M, Umans JG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F, Zhu J.

JAMA. 2008 Apr 9;299(14):1678-89. doi: 10.1001/jama.299.14.1678.

16.
17.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
18.

The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS.

Howard WJ.

Nutr Metab Cardiovasc Dis. 2010 Jun;20(5):295-300. Erratum in: Nutr Metab Cardiovasc Dis. 2011 May;21(5):390.

PMID:
20556890
19.

Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes.

Guyton JR, Betteridge DJ, Farnier M, Leiter LA, Lin J, Shah A, Johnson-Levonas AO, Brudi P.

Diab Vasc Dis Res. 2011 Apr;8(2):160-72. doi: 10.1177/1479164111406457.

PMID:
21562068
20.

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.

Daskalopoulou SS, Mikhailidis DP.

Curr Med Res Opin. 2006 Mar;22(3):511-28. Review.

PMID:
16574035

Supplemental Content

Support Center